Propanc Biopharma, Inc. Operating Income Loss

• Propanc Biopharma, Inc. showed a decrease of -3,628.9% in Operating Income Loss from 2024 to 2025.
• This data is from Propanc Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), Propanc Biopharma, Inc.'s Operating Income Loss has declined by 2,462.4%.
• Historical annual values: Fiscal year 2025: -$57.28 million | Fiscal year 2024: -$1.54 million | Fiscal year 2023: -$1.78 million | Fiscal year 2022: -$1.99 million | Fiscal year 2021: -$1.81 million | Fiscal year 2020: -$3.49 million | Fiscal year 2019: -$2.61 million | Fiscal year 2018: -$3.96 million | Fiscal year 2017: -$5.74 million | Fiscal year 2016: -$6.90 million | Fiscal year 2015: -$1.71 million | Fiscal year 2014: -$761.2 thousand | Fiscal year 2013: -$1.36 million | Fiscal year 2012: -$11.59 million | Fiscal year 2011: -$2.24 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026